Skip to Content

SELLAS Life Sciences Group Inc SLS

Morningstar Rating

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire Mar 28, 2024 8:05pm
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

GlobeNewswire Mar 26, 2024 11:35am
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire Mar 19, 2024 8:05pm
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

GlobeNewswire Mar 19, 2024 12:47pm
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire Mar 15, 2024 1:00pm
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

GlobeNewswire Mar 8, 2024 1:00pm
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

GlobeNewswire Mar 1, 2024 1:30pm
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

GlobeNewswire Feb 29, 2024 1:00pm
Thinking about buying stock in Telesis Bio, Sellas Life Sciences, Mitek Systems, Monopar Therapeutics, or Inpixon?

PR Newswire Feb 23, 2024 2:31pm
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

GlobeNewswire Feb 6, 2024 1:30pm
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

GlobeNewswire Jan 25, 2024 1:45pm
Sellas Life Sciences Gets Favorable Meeting Feedback From FDA

Global News Select Nov 13, 2023 2:22pm
Sellas Life Sciences Shares Rise 7.6% on Fast Track Designation for Cancer Treatment by FDA

Global News Select Oct 30, 2023 4:07pm
Sellas Life Sciences Group Gets FDA Orphan Drug Designation to Treat Type of Leukemia

Global News Select Oct 10, 2023 8:47pm

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.